Coherus BioSciences, Inc. - Common Stock (CHRS)

Competitors to Coherus BioSciences, Inc. - Common Stock (CHRS)

Amgen Inc. 

Coherus BioSciences and Amgen compete primarily in the biosimilar market, particularly in the area of monoclonal antibodies. Amgen is a well-established biopharmaceutical company with a significant portfolio of approved therapies and robust R&D capabilities. Coherus has focused on developing its own biosimilars to compete with Amgen's portfolio, aiming to provide cost-effective alternatives to Amgen's biologics. However, Amgen's extensive experience and established market presence give it a competitive advantage over Coherus.

Boehringer Ingelheim

Boehringer Ingelheim is another strong competitor in the biosimilars space, and particularly competes with Coherus on the development of biosimilars for various blocks of biologic drugs in immunology and oncology. Boehringer Ingelheim has a successfully established track record, advanced research capabilities, and a broad global distribution network. Coherus, while having innovative products in development, faces challenges in matching Boehringer's scale and experience in the biosimilar market, which gives the latter a competitive advantage.

Mylan N.V.

Mylan is a key competitor to Coherus in the biosimilar sector, as both companies strive to develop and market biosimilars to existing biologic therapies. Mylan has a broader portfolio and a strong global footprint, which allows it to leverage economies of scale, while Coherus focuses on specific biosimilars that address high-demand markets. Mylan's established reputation and extensive distribution networks provide it with a competitive edge in reaching customers faster and more efficiently than Coherus.

Pfizer Inc. 

Coherus competes with Pfizer in the biosimilar arena, especially as Pfizer continues to expand its portfolio of biosimilars in various therapeutic areas. Pfizer's strong clinical development pipeline, financial resources, and integrated manufacturing capabilities provide it with a significant advantage in terms of bringing biosimilars to market quickly and effectively. Coherus, with its more niche focus, lacks the expansive resources and diverse pipeline of Pfizer but aims to carve out a presence in specific markets distressed by rising costs of branded biologic therapies.

Sandoz (a Novartis division)

Sandoz, the generics and biosimilars division of Novartis, is a formidable competitor to Coherus BioSciences. Sandoz has a strong history in the development of biosimilars and has successfully launched multiple products in the market. Their global expertise in market access and regulatory strategy helps them navigate the complex landscape of biosimilars more effectively than Coherus. While Coherus seeks to differentiate itself by focusing on specific biosimilar drug candidates, Sandoz's extensive portfolio and market presence give it an edge in competitive situations.